“In Surprise Decision, FDA Blocks Crucial Cognitive Claim for Takeda’s Brintellix”

1
573

Takeda and Lundbeck had prepared to advertise that their latest antidepressant Brintellix (Vortioxetine) could give patients a cognitive boost and help them think and pay attention. While the FDA agreed that cognitive dysfunction in major depressive disorder is “a legitimate target for drug development,” they did not approve the claims for this drug.

Article →

1 COMMENT

  1. What I want to know is how this drug supposedly does this. I suspect that this is another useless “antidepressant” developed to part gullible and sad people from their money. I don’t trust anything that drug companies want to put on the market, not only psychiatric drugs but drugs of any kind. I am truly surprised that the FDA said no to the companies.

    Report comment

LEAVE A REPLY